The deal is set to close in 2017.
One benefit of Johnson & Johnson’s recently announced plan to acquire Abbott Medical Optics: It will bring the professions of optometry and ophthalmology closer together.
That’s according to Ashley McEvoy, who serves as group chairman for J&J Vision Care Cos.
McEvoy tells Healio: “Their primary call point is ophthalmology, ours is optometry.” In her view, the deal will serve as “a beautiful potential marriage in this community” as far as taking care of eyecare patients.
Earlier this month, Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire Abbott Medical Optics, a wholly owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. The acquisition will include ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health.
The transaction is expected to close in the first quarter of 2017.
McEvoy has previously said the deal will help Johnson & Johnson, which operates a contact lens business, to “become a more broad-based leader in vision care.”